Biotech Values

[mcbio]

Any thoughts on Squarer & Holden? The BOD appointments look OK. Nereus, Dr. Holden's employer for the past 7 years appears to be dying a quiet death w/o getting anything beyond P2. Last clinical trial update, a completed P2 over a year ago. No PR in almost two years. Prior to that, they'd kick out 2 or 3 PRs per year. Makes me wonder about Holden's effectiveness these days. Or maybe he just hired into a company that turned out to have loser compounds, and there was nothing he could have done about it.

Has Squarer ever led anything resembling a development stage research boutique? Hospira and Array aren't too similar, and they're awfully vague about his prior career posts.

I don't know much about Squarer and Holden so don't really have much to add on the hires. I will say generally speaking, though, that I don't think the hires have any impact on the pending ASCO data for ARRY and that to me is what is key for ARRY short-term. We could talk about what the hires mean longer-term for ARRY but, even then, what I view as ARRY's most important assets in the MEKs are already tied up in big pharma's hands. So, I don't think the hires will have much impact on the MEK programs; presumably there will be more impact on ARRY's unpartnered pipeline, but I view that as less consequential than the partnered MEKs.